Loading clinical trials...
Loading clinical trials...
An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
The study was a three-arm, active-control, multi-centre, parallel group study.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Urology Centers of Alabama
Homewood, Alabama, United States
Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States
Advanced Urology Medical Center
Anaheim, California, United States
Pacific Clinical Center
Beverly Hills, California, United States
Simi-San Faernando Valley Urology Associates
Granada Hills, California, United States
South Orange County Medical Research Center
Laguna Woods, California, United States
Western Clinical Research
Torrance, California, United States
Urology Associate PC
Denver, Colorado, United States
University of Colorado
Denver, Colorado, United States
South Florida Medical Research
Aventura, Florida, United States
Start Date
February 1, 2006
Primary Completion Date
October 1, 2007
Completion Date
October 1, 2007
Last Updated
December 19, 2012
620
ACTUAL participants
Degarelix
DRUG
Degarelix
DRUG
Leuprolide 7.5 mg
DRUG
Lead Sponsor
Ferring Pharmaceuticals
NCT06842498
NCT04550494
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05691465